Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation

BMC Musculoskeletal Disorders

Anne C Bay-Jensen³  Morten Asser Karsdal³  Hans Christian Hoeck²  Thomas Eskehave²  Lars Arendt-Nielsen⁵  Kristian Kjær Petersen⁵  Ole Simonsen⁴  Qinlong Zheng¹  Di Su¹  Jianxia Wang¹  Niels Ulrik Brandt-Hansen³  Anne Sofie Siebuhr³  Yi He³ 

[1] Nordic Bioscience China, Zhongguancun Life Science Park, 102206 Beijing, P.R. China;Center for Clinicl and Basic Research and C4Pain, Aalborg, Denmark;Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark;Department of Orthopedic Surgery, Aalborg University Hospital, Hobrovej 19, 9000 Aalborg, Denmark;Department of Health Science and Technology, Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark

关键词: Inflammation;    Type II collagen;    Biomarkers;    Cartilage degradation;    Type X collagen;    Osteoarthritis;    Hypertrophic chondrocytes;   

Others  :  1122090
DOI  :  10.1186/1471-2474-15-309

 received in 2013-11-26, accepted in 2014-09-18,  发布年份 2014

【 摘 要 】

Background

Osteoarthritis (OA) is the most common degenerative joint disease, of which the pathogenesis is inadequately understood. Hypertrophy-like changes have been observed as part of the progression of OA. The aim of the study was to develop and characterize a novel biomarker of chondrocytes hypertrophy and investigate how this marker was associated with cartilage degradation and inflammation in patients with various degrees of OA.

Methods

A competitive ELISA, C-Col10, applying a well-characterized monoclonal antibody was developed as a biomarker of chondrocyte hypertrophy through measurement of type X collagen (ColX). The levels of C-Col10, C2M (matrix metalloproteinase-derived fragments of type II collagen) and hsCRP (high sensitive C-reactive protein) were quantified by ELISAs in serum of 271 OA patients stratified by Kellgren-Lawrence (KL) score 0–4. Associations between serum levels of the three biomarkers (log transformed) were analyzed by Pearson’s correlation and differences in C-Col10 levels between patients with high and low levels of inflammation measured by hsCRP were analyzed by ANOVA.

Results

We developed a C-Col10 assay measuring the C-terminus of ColX. We found significantly higher levels of ColX in patients with KL score 2 compared to patients with no radiographic evidence of OA (KL0) (p = 0.04). Levels of ColX were significantly elevated in OA patients with above normal hsCRP levels (p < 0.0001), as well as significantly correlated with levels of C2M (r = 0.55, p < 0.0001), which suggested that chondrocyte hypertrophy was associated with inflammation and cartilage degradation. There was no correlation between C2M and hsCRP. Age and BMI adjustment didn’t change the results. Immuno-staining revealed that ColX was predominately located around the hypertrophic chondrocytes and the clustered chondrocytes indicating that C-Col10 measures may be linked to cartilage hypertrophic changes.

Conclusions

We developed a novel assay, C-Col10, for measurement of chondrocyte hypertrophy and found its levels significantly elevated in OA patients with KL score of 2, and also in OA patients with above normal hsCRP levels. Concentration of C-Col10 strongly correlated with levels of C2M, a marker of cartilage destruction. The data suggest that chondrocyte hypertrophy and subsequent collagen X fragmentation seem to be increased in a subset of patients with inflammatory OA.

【 授权许可】

   
2014 He et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA: Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009, 60(12):3546-3553.
• [2]Bertrand J, Cromme C, Umlauf D, Frank S, Pap T: Molecular mechanisms of cartilage remodelling in osteoarthritis. Int J Biochem Cell Biol 2010, 42(10):1594-1601.
• [3]Mackie EJ, Ahmed YA, Tatarczuch L, Chen KS, Mirams M: Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol 2008, 40(1):46-62.
• [4]Gelse K, Ekici AB, Cipa F, Swoboda B, Carl HD, Olk A, Hennig FF, Klinger P: Molecular differentiation between osteophytic and articular cartilage–clues for a transient and permanent chondrocyte phenotype. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 2012, 20(2):162-171.
• [5]Saito M, Sasho T, Yamaguchi S, Ikegawa N, Akagi R, Muramatsu Y, Mukoyama S, Ochiai N, Nakamura J, Nakagawa K, Nakajima A, Takahashi K: Angiogenic activity of subchondral bone during the progression of osteoarthritis in a rabbit anterior cruciate ligament transection model. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 2012, 20(12):1574-1582.
• [6]Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, Rutsch F, Schafer FK, Niggemeyer O, Steinhagen J, Lohmann CH, Pap T, Rüther W: Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009, 60(9):2694-2703.
• [7]Higashikawa A, Saito T, Ikeda T, Kamekura S, Kawamura N, Kan A, Oshima Y, Ohba S, Ogata N, Takeshita K, Nakamura K, Chung UI, Kawaguchi H: Identification of the core element responsive to runt-related transcription factor 2 in the promoter of human type X collagen gene. Arthritis Rheum 2009, 60(1):166-178.
• [8]Dreier R: Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res Ther 2010, 12(5):216. BioMed Central Full Text
• [9]van der Kraan PM, van den Berg WB: Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 2012, 20(3):223-232.
• [10]Pitsillides AA, Beier F: Cartilage biology in osteoarthritis–lessons from developmental biology. Nat Rev Rheumatol 2011, 7(11):654-663.
• [11]Bruckner P, van der Rest M: Structure and function of cartilage collagens. Microsc Res Tech 1994, 28(5):378-384.
• [12]Kwan AP, Sear CH, Grant ME: Identification of disulphide-bonded type X procollagen polypeptides in embryonic chick chondrocyte cultures. FEBS Lett 1986, 206(2):267-272.
• [13]Schmid TM, Mayne R, Jeffrey JJ, Linsenmayer TF: Type X collagen contains two cleavage sites for a vertebrate collagenase. J Biol Chem 1986, 261(9):4184-4189.
• [14]Schmid TM, Popp RG, Linsenmayer TF: Hypertrophic cartilage matrix. Type X collagen, supramolecular assembly, and calcification. Ann N Y Acad Sci 1990, 580:64-73.
• [15]Kwan AP, Cummings CE, Chapman JA, Grant ME: Macromolecular organization of chicken type X collagen in vitro. J Cell Biol 1991, 114(3):597-604.
• [16]Luckman SP, Rees E, Kwan AP: Partial characterization of cell-type X collagen interactions. Biochem J 2003, 372(Pt 2):485-493.
• [17]Aigner T, Reichenberger E, Bertling W, Kirsch T, Stoss H, von der Mark K: Type X collagen expression in osteoarthritic and rheumatoid articular cartilage. Virchows Arch B Cell Pathol Incl Mol Pathol 1993, 63(4):205-211.
• [18]Hoyland JA: Distribution of type X collagen mRNA in normal and osteoarthritic human cartilage. Bone Miner 1991, 15(2):151-163.
• [19]Walker GD, Fischer M, Gannon J, Thompson RC Jr, Oegema TR Jr: Expression of type-X collagen in osteoarthritis. J Orthop Res: official publication Orthop Res Soc 1995, 13(1):4-12.
• [20]Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, Uchida M, Ogata N, Seichi A, Nakamura K, Kawaguchi H: Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 2005, 13(7):632-641.
• [21]Matsumoto T, Cooper GM, Gharaibeh B, Meszaros LB, Li G, Usas A, Fu FH, Huard J: Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum 2009, 60(5):1390-1405.
• [22]Huebner JL, Johnson KA, Kraus VB, Terkeltaub RA: Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 2009, 17(8):1056-1064.
• [23]Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY: Articular chondrocyte apoptosis in equine osteoarthritis. Vet J London, England: 1997 2003, 166(1):52-57.
• [24]Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P, Richard S, Vignon E: Increased serum C-reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. Rev Rhum Engl Ed 1998, 65(12):759-765.
• [25]Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB: Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997, 40(4):723-727.
• [26]Smith JW, Martins TB, Gopez E, Johnson T, Hill HR, Rosenberg TD: Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes. Ther Adv musculoskelet Dis 2012, 4(5):315-325.
• [27]Scanzello CR, Goldring SR: The role of synovitis in osteoarthritis pathogenesis. Bone 2012, 51(2):249-257.
• [28]Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R: Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol 2005, 175(12):8296-8302.
• [29]Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, Leeming DJ, Dam EB, Zheng Q, Qvist P, Karsdal MA: Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM–increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44(5–6):423-429.
• [30]Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA: Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 2012, 32(11):3565-3572.
• [31]Bay-Jensen AC, Wichuk S, Byrjalsen I, Leeming DJ, Morency N, Christiansen C, Karsdal MA, Maksymowych WP: Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 2013, 8(1):e54504.
• [32]Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, Milz S: Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004, 24(6):3743-3748.
• [33]Welgus HG, Fliszar CJ, Seltzer JL, Schmid TM, Jeffrey JJ: Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J Biol Chem 1990, 265(23):13521-13527.
• [34]Fitzgerald JB, Jin M, Chai DH, Siparsky P, Fanning P, Grodzinsky AJ: Shear- and compression-induced chondrocyte transcription requires MAPK activation in cartilage explants. J Biol Chem 2008, 283(11):6735-6743.
• [35]Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y: Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008, 67(Suppl 3):iii75-iii82.
• [36]Conrozier T, Carlier MC, Mathieu P, Colson F, Debard AL, Richard S, Favret H, Bienvenu J, Vignon E: Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis 2000, 59(10):828-831.
• [37]Wolfe F: The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol 1997, 24(8):1486-1488.
• [38]Sturmer T, Brenner H, Koenig W, Gunther KP: Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis 2004, 63(2):200-205.
• [39]Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, Nishida N, Akune T, Yoshimura N, Nakagawa T, Nakamura K, Tokunaga K, Chung UI, Kawaguchi H: Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat Med 2010, 16(6):678-686.
• [40]Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, Min BH, Chun JS: Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010, 16(6):687-693.
• [41]Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R: Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum 2005, 52(1):144-154.
• [42]Cecil DL, Terkeltaub R: Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol 2008, 180(12):8378-8385.
• [43]Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW: Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60(12):3723-3733.
• [44]Mwale F, Rampersad S, Richard H, Guoying Y, Al Rowas S, Madiraju P, Antoniou J, Laverty S: The constitutive expression of type x collagen in mesenchymal stem cells from osteoarthritis patients is reproduced in a rabbit model of osteoarthritis. J Tissue Eng 2011, 2011:587547.
• [45]Brew CJ, Clegg PD, Boot-Handford RP, Andrew JG, Hardingham T: Gene expression in human chondrocytes in late osteoarthritis is changed in both fibrillated and intact cartilage without evidence of generalised chondrocyte hypertrophy. Ann Rheum Dis 2010, 69(1):234-240.
• [46]Chen-An P, Andreassen KV, Henriksen K, Li Y, Karsdal MA, Bay-Jensen AC: The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage. PLoS One 2012, 7(6):e40081.